Bentley Pharmaceuticals, Inc. engages in the research, development, licensing, and commercialization of generic and branded pharmaceutical products, active pharmaceutical ingredients, and drug delivery technologies in Europe, northern Africa, the Middle East, and the United States. Its drug technologies include CPE-215 permeation platform technology, which consists of chemical compounds that enable the absorption of drugs across biological membranes; solubility enhancement technology involving chemical and manufacturing procedures for enhancing compound solubility; oral formulation technologies; and nanocaplet technology for the delivery of macromolecule therapeutics. It offers products in four therapeutic areas: cardiovascular, gastrointestinal, central nervous system, and infectious diseases. Bentley's branded pharmaceutical products include Belmalip, Belmazol, Cimascal D Forte, Codeisan, Enalapril Belmac, Ibumac, Lanzol, Mio Relax, Pentoxifilina Belmac, Senioral, and Xetin. Its generic pharmaceutical products primarily comprise Amlodapino Davur, Amlodapino Rimafar, Amoxicilina Belmac, Amox/Clavulanico Davur, Azitromicina Davur, Cardidopa/Levodopa Davur, Ciprofloxacino Davur, Ebastina Davur, Enalapril Davur, Finasterida Davur, Fluoxetina Davur, Fluoxetina Belmac, Fluoxetina Rimafar, Ibuprofeno Davur, Lansoprazol Rimafar, Lansoprazol Davur, Omeprazol Davur, Omeprazol Rimafar, Paroxetina Davur, Paroxetina Rimafar, Pentoxifilina Davurm, Pravastatina Davur, Pravastatina Rimafar, Sertralina Davur, Simvastatina Davur, Simvastatina Rimafar, and Trimetazidina Davur. The company also developed a topical nail lacquer for onychomycosis; topical hormonal therapies; and intranasal pain management products. Its products under development stage include intranasal insulin, which is in Phase I/II clinical stage, for diabetes; an oral peptide delivery technology; and various generic products. The company was founded in 1974 and is headquartered in Exeter, New Hampshire.